OSU03013

03/15/2008 - "Our molecular and proteomic results show the potential of OSU03013 as an anticancer drug for lung cancer."
03/15/2008 - "Our results indicated that OSU03013 had low-dose (1 approximately 4 microM) cytotoxicity in all lung cancer cell lines tested 48 hours posttreatment. "
03/15/2008 - "Cytotoxicity and proteomics analyses of OSU03013 in lung cancer."
04/01/2006 - "The aim of the present studies was to investigate the potential of a celecoxib-derived PDK1 inhibitor (OSU03013), that does not inhibit cyclooxygenase-2, to kill lung cancer cells in vitro. "
03/15/2008 - "We identified for the first time that OSU03013 inhibits cAMP-dependent protein kinase activity and causes dephosphorylation of glycogen synthase kinase 3-beta leading to beta-catenin degradation, which is often overexpressed in lung cancer. "

04/01/2006 - "Using human non-small-cell lung cancer A549 cells, OSU03013 dose-dependently induced apoptosis. "
12/01/2017 - "Herein, we review the research on using current chemotherapy drugs and natural compounds (Wortmannin and Roscovitine, Cordyceps militaris, Resveratrol, OSU03013, Myricetin, Berberine, Antroquinonol) and the beneficial effects they have on various types of cancers including non-small cell lung cancer. "

12/01/2017 - "Herein, we review the research on using current chemotherapy drugs and natural compounds (Wortmannin and Roscovitine, Cordyceps militaris, Resveratrol, OSU03013, Myricetin, Berberine, Antroquinonol) and the beneficial effects they have on various types of cancers including non-small cell lung cancer. "